FORE Biotherapeutics (Series D-2 Extension)
Funding Details
Awarder
Inbox
Date Award
July 14, 2026
Vertical
Biotechnology
Funding URL
View Funding Page
Valuation
$3,000,000
Funding Amount
$67,400,000
Company Info
Market
Oncology
Location
Philadelphia, PA, USA
Coinvestors
3B Future Health Fund, Axil Capital, Cormorant Asset Management, HBM Healthcare Investments, LG Technology Ventures, Medicxi, Novartis Venture Funds, OrbiMed Advisors, Primer Ventures, Samsung Ventures, SR One, Symbiosis, TaiAx, Wellington Management, Windham Life Science Partners
Company Description

FORE is a registration stage targeted oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company's lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor rationally designed with a first-in-class mechanism to address treatment gaps from 1st and 2nd generation BRAF inhibitors.

Links
Website
Back to HomeBack to Biotechnology DealsView Funding Announcement